Key facts
- Theragen’s last known valuation is $41.3M (Jun 2017).
- It has raised $10.4M; the latest was Later Stage VC in Nov 2025.
- Notable investors include Ballast Point Ventures, K2 HealthVentures.
- Status: Privately Held (backing).
Investors
2- ·The complete investor list — 2 names
- ·Watchlist + deal alerts for Theragen
- ·The full record, as it builds
Funding rounds
No funding rounds for Theragen are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Theragen
Developer of a bone stimulation device intended for body healing and pain relief. The company's technology delivers a bone growth stimulator system by combining all-day wearability, proven capacitive coupling therapy, and automated daily clinical data capture to engage patients, enable compliance, and generate insight reports to inform clinicians when patients need guidance to stay on their healing journey, enabling patients to get relief from various kinds of pain and live a healthy life.
- Sector
- Healthcare
- HQ
- Jacksonville, FL, United States
- Founded
- 2014
- Employees
- 181
- Website
- actastim.com/
- Ownership
- Privately Held (backing)
Theragen doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Theragen shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Theragen in its N-PORT filings yet. We sweep new filings monthly.